Brief: Acorda Therapeutics Announces Revised Long-Term Financial Guidance

Acorda Therapeutics

22/12/2022 13:07

Dec 22 (Reuters) - Acorda Therapeutics Inc  ACOR.O :
    * ACORDA THERAPEUTICS ANNOUNCES REVISED LONG-TERM FINANCIAL
GUIDANCE
    * REVISED GUIDANCE CORRECTS CERTAIN ERRORS IDENTIFIED IN
YEAR-END
BUDGETING PROCESS
    * ERRORS IDENTIFIED IN YEAR-END BUDGETING PROCESS OVERSTATED
PROJECTED ADJUSTED EBITDA AND ENDING CASH BALANCES FOR 2022-2027
    * REVISED GUIDANCE ALSO REFLECTS UPDATES FROM ACTUAL
FINANCIAL
RESULTS FROM OCT AND NOV 2022 AND FROM YEAR-END BUDGETING
PROCESS
    * UPDATES INCLUDE COMPANY'S PROJECTED SALES OF INBRIJA
OUTSIDE
UNITED STATES AND TOTAL INBRIJA SALES FOR 2024-2027
    * REVISED LONG-TERM GUIDANCE DOES NOT AFFECT ACORDA'S
PREVIOUSLY
REPORTED FINANCIAL RESULTS FOR PERIOD ENDED SEPT 30, 2022
    * REVISED LONG-TERM FINANCIAL GUIDANCE DOES NOT AFFECT
INBRIJA
U.S. NET REVENUE GUIDANCE FOR 2022 OF BETWEEN $27.8 - $28.7
MILLION
    * ACORDA THERAPEUTICS INC SEES 2023 NET REVENUE $122.2
MILLION -
$135.1 MILLION
    * FINNISH GOVERNMENT ADVISED CO IT SATISFIED ALL CONDITIONS
TO
RECEIVE WAIVER OF ABOUT $27.0 MILLION OF LOANS INCLUDING ACCRUED
INTEREST ISSUED TO UNIT

Source text for Eikon:  ID:nBwcgnTy8a 
Further company coverage:  ACOR.O 
 ((Reuters.Briefs@thomsonreuters.com))